Detection of Human P2X sub(7) Nucleotide Receptor Polymorphisms by a Novel Monocyte Pore Assay Predictive of Alterations in Lipopolysaccharide-Induced Cytokine Production

The nucleotide receptor P2X sub(7) is expressed by most leukocytes and initiates signaling events that amplify numerous LPS responses. We tested the hypothesis that loss-of-function polymorphisms in the human P2X sub(7) gene predispose to the production of an anti-inflammatory mediator balance. Accordingly, we developed a novel P2X sub(7) pore assay in whole blood that magnifies the activity from wild-type alleles and preserves the gene dosage effect for the 1513 C polymorphism (AA, 69 +/-4; AC, 42 +/-4; and CC, 6 +/-1- fold stimulation). Thirty of 200 healthy individuals were identified as having low P2X sub(7) pore activity. Seven low pore subjects were 1513 CC, 3 and 11 participants had the other known variants 946 GA and 1729 TA respectively; the remaining 9 volunteers likely have novel polymorphisms. Because platelets are a large source of extracellular ATP during inflammation, whole blood was treated ex vivo with Salmonella typhimurium LPS in the absence of exogenous nucleotides. LPS-stimulated whole blood from individuals in the low pore activity group generated reduced plasma levels of TNF- alpha (p = 0.036) and higher amounts of IL- 10 (p < 0.001) relative to the high pore controls. This reduction in the TNF- alpha to IL-10 ratio persisted to at least 24 h and is further decreased by cotreatment with 2-methylthio-ATP. The ability of P2X sub(7) polymorphisms to regulate the LPS-induced TNF- alpha to IL-10 ratio suggests that 15% of healthy adults may exhibit anti-inflammatory mediator responses during major infectious perturbations of the immune system, which can be predicted by P2X sub(7) pore activity.